Pretargeting methods and novel pretargeting conjugates
    61.
    发明公开
    Pretargeting methods and novel pretargeting conjugates 失效
    预先指定Verfahren und neon Konjugate zum预定位

    公开(公告)号:EP1346730A1

    公开(公告)日:2003-09-24

    申请号:EP03008765.4

    申请日:1994-12-07

    申请人: NEORX CORPORATION

    IPC分类号: A61K47/48 A61P7/02

    摘要: In one aspect the invention includes an "antibody cocktail" approach to multi-step targeting of an active agent to a target site. This comprises administering multiple targeting moiety conjugates, wherein the targeting moieties are antibodies with nonoverlapping patterns of cross-reactivity for epitopes at the target site and wherein each targeting conjugate has a ligand or anti-ligand that is complementary to a corresponding anti-ligand or ligand on the active agent conjugate. In a further aspect the invention includes a multi-step method for targeting specifically a thrombolytic agent to the site of a thrombus, wherein the targeting moiety may be an annexin. In another aspect annexin may be the targeting moiety in a multi-step method for delivery of an active agent to a site having exposed anionic membrane lipids. In a final aspect, the invention includes specifically the compound biotinamido-N-methylglycyl-seryl-O-succinamido-benzyl DOTA, a chelating structure which may be used to deliver radiometals to a target site.

    摘要翻译: 在一个方面,本发明包括用于将活性剂多步靶向目标部位的“抗体混合物”方法。 这包括施用多个靶向部分缀合物,其中靶向部分是在靶位点处表位具有不重叠的交叉反应模式的抗体,并且其中每个靶向缀合物具有与相应的抗配体或配体互补的配体或抗配体 在活性剂缀合物上。 在另一方面,本发明包括用于将血栓溶解剂特异性靶向血栓部位的多步法,其中靶向部分可以是膜联蛋白。 在另一方面,膜联蛋白可以是用于将活性剂递送到具有暴露的阴离子膜脂质的部位的多步骤方法中的靶向部分。 在最后方面,本发明具体包括化合物生物素酰氨基-N-甲基甘氨酰 - 丝氨酰基-O-琥珀酰氨基 - 苄基DOTA,其可用于将靶向部位递送放射性金属的螯合结构。

    PREPARATION OF POLYMERISATION CATALYSTS
    68.
    发明授权
    PREPARATION OF POLYMERISATION CATALYSTS 有权
    用于生产聚合催化剂

    公开(公告)号:EP1102777B1

    公开(公告)日:2002-12-18

    申请号:EP99936818.6

    申请日:1999-07-30

    摘要: A process is described for producing a transition metal complex of formula (B) wherein M is Fe[II], Fe[III], Co[I], Co[II], Co[III], Mn[I], Mn[II], Mn[III], Mn[IV], Ru[II], Ru[III] or Ru[IV]; X represents an atom or group covalently or ionically bonded to the transition metal M; T is the oxidation state of the transition metal M and b is the valency of the atom or group X; R , R , R , R , R , R and R are independently selected from hydrogen, halogen, hydrocarbyl, substituted hydrocarbyl, heterohydrocarbyl or substituted heterohydrocarbyl; and when any two or more of R - R are hydrocarbyl, substituted hydrocarbyl, heterohydrocarbyl or substituted heterohydrocarbyl, said two or more can be linked to form one or more cyclic substituents; comprising reacting together in a single stage reaction components comprising (1) precursors capable of forming Ligand (B) and (2) a compound of the formula M[T]-(T/b)X. The complex has utility as a catalyst for the polymerisation of 1-olefins.